title: ABLETOP, a well-tolerated, effective regimen for relapsing Hodgkin's disease. Swiss Group for Clinical Cancer Research (SAKK).
abstract: ABLETOP, a salvage regimen for relapsing Hodgkin's disease consisting of adriamycin, bleomycin and etoposide, has been evaluated in 18 patients, 16 of whom were evaluable for toxicity and 15 for response. Fourteen patients showed maximal grade II nausea and vomiting, whereas 13 patients had grade III/IV alopecia. The median leukocyte nadir was 3.1 x 10(3)/mm3. Twelve of 15 patients evaluable for response reached a complete or partial remission; 10 of 12 pretreated patients reached a remission, 5 a complete remission and 5 a partial remission, for an overall response rate of 83%. We conclude that ABLETOP is a well-tolerated effective regimen for relapsing Hodgkin's disease.
authors: Division of Oncology, Kantonsspital Basle, Switzerland.
authors: R
authors: R
authors: Obrist
authors: H P
authors: HP
authors: Honegger
authors: M
authors: M
authors: Aapro
authors: K
authors: K
authors: Bürki
authors: F
authors: F
authors: Cavalli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D001761:Bleomycin; D005047:Etoposide; D004317:Doxorubicin